George Lau, MD, FRCP, FAASLD
Articles
Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC
August 2nd 2023George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
Read More
Dr Lau on the Association of irAEs and OS in the HIMALAYA Study in HCC
June 28th 2023George Lau, MD, FRCP, FAASLD, discusses the association between immune-related adverse effects and overall survival for patients with unresectable hepatocellular carcinoma enrolled on the phase 3 HIMALAYA trial.
Read More
Latest Updated Articles
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: September 17th 2024 | Updated: September 21st 2024
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
